Telcon RF Pharmaceutical has completed its capital reduction without compensation.

Telcon RF Pharmaceutical Completes Capital Reduction Without Compensation...Trading Resumes View original image

On June 30, Telcon RF Pharmaceutical announced that it had completed the capital reduction procedure and would resume trading through a change of listing.


Telcon RF Pharmaceutical finished a 10-to-1 capital reduction without compensation on June 9 to offset its accumulated losses. Based on this, the company plans to strengthen the competitiveness of its pharmaceutical business division.


The company also intends to increase investment in production and logistics infrastructure. To enhance productivity, Telcon RF Pharmaceutical plans to build a palletizer and construct a new high rack warehouse with 2,000 cells to improve the efficiency of inbound and outbound operations for products from contract manufacturers.



A representative of Telcon RF Pharmaceutical stated, "We are reinforcing our business foundation so that we can stably generate more than 30 billion won in annual sales through expanded production capacity and facility investments in the pharmaceutical business division."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing